Journavx was approved by the FDA in late January.
Pershing is hopeful it’ll make an impact in reducing addiction but wants to see the new drug in use before casting a final judgment. “When oxycodone was released, Purdue Pharma told everyone this was ...
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next
Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq ...
Ark Clinical Research at the Forefront of Advancing Non-Opioid Pain Research
The FDA’s landmark approval of Journavx (suzetrigine)—the first non-opioid pain reliever in over two decades—represents a breakthrough in pain management. This breakthrough underscores the urgent need ...